<p>Assenagon Asset Management S.A. 在最近向美國證券交易委員會提交的 13F 表格中披露，在第三季度將其在 Rhythm Pharmaceuticals, Inc.（NASDAQ:RYTM - 免費報告）的持股減少了 5.8%。該公司在此期間出售了 13,870 股後，持有 224,128 股該公司的股票。截至其最近的 SEC 文件，Assenagon Asset Management S.A. 持有 Rhythm Pharmaceuticals 0.34% 的股份，價值 22,635,000 美元。</p>
<p>獲取 <strong>Rhythm Pharmaceuticals</strong> 警報：</p>
<ul>
<li>7 只將推動減肥藥市場的股票</li>
</ul>
<p>其他一些機構投資者和對沖基金最近也增加或減少了對該公司的投資。Rhumbline Advisers 在第一季度將其在 Rhythm Pharmaceuticals 的持股增加了 3.6%。Rhumbline Advisers 現在持有 85,719 股該公司的股票，價值 4,541,000 美元，此前在上個季度購買了額外的 2,988 股。Siren L.L.C. 在第一季度購買了 Rhythm Pharmaceuticals 的新頭寸，估計價值約為 14,701,000 美元。Voleon Capital Management LP 在第一季度購買了 Rhythm Pharmaceuticals 的新頭寸，估計價值約為 732,000 美元。Intech Investment Management LLC 在第一季度將其在 Rhythm Pharmaceuticals 的持股增加了 20.7%。Intech Investment Management LLC 現在持有 33,893 股該公司的股票，價值 1,795,000 美元，此前在此期間購買了額外的 5,801 股。最後，Harbor Capital Advisors Inc. 在第二季度將其在 Rhythm Pharmaceuticals 的頭寸增加了 12.0%。Harbor Capital Advisors Inc. 現在持有 86,546 股該公司的股票，價值 5,469,000 美元，此前在上個季度收購了額外的 9,249 股。</p>
<h2>Rhythm Pharmaceuticals 價格表現</h2>
<p>RYTM 股票在週五開盤價為 112.14 美元。Rhythm Pharmaceuticals, Inc. 的 1 年最低價為 45.90 美元，1 年最高價為 122.20 美元。該公司的 50 日移動平均價格為 106.54 美元，200 日移動平均價格為 93.80 美元。該股票的市值為 74.8 億美元，市盈率為 -36.17，貝塔值為 1.96。</p>
<ul>
<li>2 家生物科技公司有前景的減肥藥即將推出</li>
</ul>
<p>Rhythm Pharmaceuticals（NASDAQ:RYTM - 獲取免費報告）最近於 11 月 4 日發佈了季度財報。該公司報告季度每股收益為（$0.82），低於市場共識預期的（$0.72）$0.10。Rhythm Pharmaceuticals 的股本回報率為 -433.21%，淨利潤率為 -110.32%。該公司在本季度的收入為 5,130 萬美元，而市場共識預期為 5,071 萬美元。整體來看，分析師預計 Rhythm Pharmaceuticals, Inc. 本年度每股收益將為 -4.32。</p>
<h2>內部買賣</h2>
<p>在其他消息中，內部人士 Pamela J. Cramer 於 12 月 11 日星期四出售了 3,350 股 Rhythm Pharmaceuticals 股票。該股票以平均價格 111.00 美元出售，總價值為 371,850.00 美元。出售完成後，內部人士直接持有該公司 20,814 股，價值 2,310,354 美元。此次交易使其持股減少了 13.86%。該出售在向 SEC 的法律文件中披露，文件可通過此鏈接獲取。此外，內部人士 Joseph Shulman 於 10 月 30 日星期四出售了 9,748 股該股票。該股票以平均價格 115.24 美元出售，總交易額為 1,123,359.52 美元。交易完成後，內部人士持有該公司 8,509 股，價值約 980,577.16 美元。此次交易使其持股減少了 53.39%。該出售的披露在 SEC 文件中可獲得。內部人士在上個季度出售了價值 3,436,340 美元的 30,350 股公司股票。公司內部人士持有該公司 6.10% 的股份。</p>
<h2>分析師評級變動</h2>
<p>一些研究公司最近對 RYTM 發表了評論。Guggenheim 將 Rhythm Pharmaceuticals 的目標價格從 120.00 美元上調至 140.00 美元，並在週三的研究報告中給予該公司 “買入” 評級。Cowen 在 12 月 11 日星期四的研究報告中重申了對 Rhythm Pharmaceuticals 股票的 “買入” 評級。瑞銀集團在週三的研究報告中重申了對 Rhythm Pharmaceuticals 股票的 “買入” 評級。JMP Securities 在 9 月 25 日星期四的研究報告中將 Rhythm Pharmaceuticals 股票的目標價格從 135.00 美元上調至 142.00 美元，並給予該股票 “市場表現優於大盤” 評級。最後，Oppenheimer 在 11 月 5 日星期三的研究報告中將 Rhythm Pharmaceuticals 股票的評級從 “表現優於大盤” 下調至 “市場表現”。一位研究分析師給予該股票 “強烈買入” 評級，十六位分析師給予 “買入” 評級，一位分析師給予 “持有” 評級，一位分析師給予 “賣出” 評級。根據 MarketBeat.com 的數據，該股票的共識評級為 “適度買入”，共識目標價格為 125.60 美元。</p>
<p><strong>閲讀我們關於 RYTM 的最新報告</strong></p>
<h2>Rhythm Pharmaceuticals 公司簡介</h2>
<p>（免費報告）</p>
<p>Rhythm Pharmaceuticals, Inc. 是一家臨牀階段的生物技術公司，致力於開發針對罕見遺傳性肥胖和代謝功能障礙的靶向療法。該公司的研究重點是黑色素皮質素-4 受體（MC4R）通路，該通路在調節食慾、能量消耗和體重方面發揮着核心作用。利用專有的肽技術，Rhythm 旨在為具有特定基因變異的患者提供精準治療，這些變異會干擾正常的體重調節。</p>
<p>該公司的主要研究產品 setmelanotide 是一種選擇性 MC4R 激動劑，旨在恢復在 POMC、LEPR 和 PCSK1 等基因缺陷患者中的信號傳導。</p>
<h2>相關文章</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Rhythm Pharmaceuticals</li>
<li>股息支付比率計算器</li>
<li>耐克盈利超預期，但在中國市場面臨挑戰並遭遇關税</li>
<li>上海證券交易所綜合指數是什麼？</li>
<li>人工智能熱潮是泡沫嗎？這兩隻股息股票表示不是</li>
<li>現在值得購買的三隻沃倫·巴菲特股票</li>
<li>2026 年四隻高潛力 ETF：小型股、太空股票等</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UllUTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UllUTQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1000 美元在 Rhythm Pharmaceuticals 嗎？</h2>
<p>在考慮 Rhythm Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前... 而 Rhythm Pharmaceuticals 並不在名單上。</p>
<p>雖然 Rhythm Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

RYTM

<p>Assenagon Asset Management S.A. 將其在 Rhythm Pharmaceuticals 的持股比例減少了 5.8%，出售了 13,870 股。Rhythm Pharmaceuticals 的股票開盤價為 112.14 美元，1 年最低價為 45.90 美元，最高價為 122.20 美元。分析師的評級不一，Guggenheim 將目標價上調至 140 美元，而 Oppenheimer 則下調至 “市場表現”。內部人士在上個季度出售了價值 3,436,340 美元的 30,350 股</p>

<p>Assenagon Asset Management S.A. cut its holdings in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 5.8% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 224,128 shares of the company's stock after selling 13,870 shares during the period. Assenagon Asset Management S.A. owned 0.34% of Rhythm Pharmaceuticals worth $22,635,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Assenagon Asset Management S.A. 在最近向美國證券交易委員會提交的 13F 表格中披露，在第三季度將其在 Rhythm Pharmaceuticals, Inc.（NASDAQ:RYTM - 免費報告）的持股減少了 5.8%。該公司在此期間出售了 13,870 股後，持有 224,128 股該公司的股票。截至其最近的 SEC 文件，Assenagon Asset Management S.A. 持有 Rhythm Pharmaceuticals 0.34% 的股份，價值 22,635,000 美元。</p>
</div><p>Get <strong>Rhythm Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Rhythm Pharmaceuticals</strong> 警報：</p>
</div><ul>
<li>7 Stocks That Will Drive the Weight Loss Drugs Market</li>
</ul>
<div class="lb-trans"><ul>
<li>7 只將推動減肥藥市場的股票</li>
</ul>
</div><p>A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Rhumbline Advisers raised its holdings in Rhythm Pharmaceuticals by 3.6% in the 1st quarter. Rhumbline Advisers now owns 85,719 shares of the company's stock worth $4,541,000 after purchasing an additional 2,988 shares in the last quarter. Siren L.L.C. purchased a new position in shares of Rhythm Pharmaceuticals during the first quarter valued at about $14,701,000. Voleon Capital Management LP purchased a new position in shares of Rhythm Pharmaceuticals during the first quarter valued at about $732,000. Intech Investment Management LLC lifted its holdings in Rhythm Pharmaceuticals by 20.7% in the first quarter. Intech Investment Management LLC now owns 33,893 shares of the company's stock worth $1,795,000 after buying an additional 5,801 shares during the period. Finally, Harbor Capital Advisors Inc. boosted its position in Rhythm Pharmaceuticals by 12.0% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 86,546 shares of the company's stock valued at $5,469,000 after acquiring an additional 9,249 shares in the last quarter.</p>
<div class="lb-trans"><p>其他一些機構投資者和對沖基金最近也增加或減少了對該公司的投資。Rhumbline Advisers 在第一季度將其在 Rhythm Pharmaceuticals 的持股增加了 3.6%。Rhumbline Advisers 現在持有 85,719 股該公司的股票，價值 4,541,000 美元，此前在上個季度購買了額外的 2,988 股。Siren L.L.C. 在第一季度購買了 Rhythm Pharmaceuticals 的新頭寸，估計價值約為 14,701,000 美元。Voleon Capital Management LP 在第一季度購買了 Rhythm Pharmaceuticals 的新頭寸，估計價值約為 732,000 美元。Intech Investment Management LLC 在第一季度將其在 Rhythm Pharmaceuticals 的持股增加了 20.7%。Intech Investment Management LLC 現在持有 33,893 股該公司的股票，價值 1,795,000 美元，此前在此期間購買了額外的 5,801 股。最後，Harbor Capital Advisors Inc. 在第二季度將其在 Rhythm Pharmaceuticals 的頭寸增加了 12.0%。Harbor Capital Advisors Inc. 現在持有 86,546 股該公司的股票，價值 5,469,000 美元，此前在上個季度收購了額外的 9,249 股。</p>
</div><h2>Rhythm Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Rhythm Pharmaceuticals 價格表現</h2>
</div><p>RYTM stock opened at $112.14 on Friday. Rhythm Pharmaceuticals, Inc. has a 1-year low of $45.90 and a 1-year high of $122.20. The business has a fifty day moving average price of $106.54 and a 200-day moving average price of $93.80. The stock has a market capitalization of $7.48 billion, a P/E ratio of -36.17 and a beta of 1.96.</p>
<div class="lb-trans"><p>RYTM 股票在週五開盤價為 112.14 美元。Rhythm Pharmaceuticals, Inc. 的 1 年最低價為 45.90 美元，1 年最高價為 122.20 美元。該公司的 50 日移動平均價格為 106.54 美元，200 日移動平均價格為 93.80 美元。該股票的市值為 74.8 億美元，市盈率為 -36.17，貝塔值為 1.96。</p>
</div><ul>
<li>2 biotechs with promising weight-loss drugs coming</li>
</ul>
<div class="lb-trans"><ul>
<li>2 家生物科技公司有前景的減肥藥即將推出</li>
</ul>
</div><p>Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.10). Rhythm Pharmaceuticals had a negative return on equity of 433.21% and a negative net margin of 110.32%.The business had revenue of $51.30 million during the quarter, compared to the consensus estimate of $50.71 million. As a group, analysts anticipate that Rhythm Pharmaceuticals, Inc. will post -4.32 earnings per share for the current year.</p>
<div class="lb-trans"><p>Rhythm Pharmaceuticals（NASDAQ:RYTM - 獲取免費報告）最近於 11 月 4 日發佈了季度財報。該公司報告季度每股收益為（$0.82），低於市場共識預期的（$0.72）$0.10。Rhythm Pharmaceuticals 的股本回報率為 -433.21%，淨利潤率為 -110.32%。該公司在本季度的收入為 5,130 萬美元，而市場共識預期為 5,071 萬美元。整體來看，分析師預計 Rhythm Pharmaceuticals, Inc. 本年度每股收益將為 -4.32。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部買賣</h2>
</div><p>In other news, insider Pamela J. Cramer sold 3,350 shares of Rhythm Pharmaceuticals stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $111.00, for a total value of $371,850.00. Following the completion of the sale, the insider directly owned 20,814 shares in the company, valued at $2,310,354. The trade was a 13.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Joseph Shulman sold 9,748 shares of the stock in a transaction that occurred on Thursday, October 30th. The shares were sold at an average price of $115.24, for a total transaction of $1,123,359.52. Following the transaction, the insider owned 8,509 shares in the company, valued at approximately $980,577.16. This trade represents a 53.39% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 30,350 shares of company stock valued at $3,436,340 over the last quarter. Company insiders own 6.10% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，內部人士 Pamela J. Cramer 於 12 月 11 日星期四出售了 3,350 股 Rhythm Pharmaceuticals 股票。該股票以平均價格 111.00 美元出售，總價值為 371,850.00 美元。出售完成後，內部人士直接持有該公司 20,814 股，價值 2,310,354 美元。此次交易使其持股減少了 13.86%。該出售在向 SEC 的法律文件中披露，文件可通過此鏈接獲取。此外，內部人士 Joseph Shulman 於 10 月 30 日星期四出售了 9,748 股該股票。該股票以平均價格 115.24 美元出售，總交易額為 1,123,359.52 美元。交易完成後，內部人士持有該公司 8,509 股，價值約 980,577.16 美元。此次交易使其持股減少了 53.39%。該出售的披露在 SEC 文件中可獲得。內部人士在上個季度出售了價值 3,436,340 美元的 30,350 股公司股票。公司內部人士持有該公司 6.10% 的股份。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>A number of research firms have recently commented on RYTM. Guggenheim raised their target price on Rhythm Pharmaceuticals from $120.00 to $140.00 and gave the company a &#34;buy&#34; rating in a research note on Wednesday. Cowen reissued a &#34;buy&#34; rating on shares of Rhythm Pharmaceuticals in a research report on Thursday, December 11th. UBS Group reaffirmed a &#34;buy&#34; rating on shares of Rhythm Pharmaceuticals in a research report on Wednesday. JMP Securities increased their price target on shares of Rhythm Pharmaceuticals from $135.00 to $142.00 and gave the stock a &#34;market outperform&#34; rating in a research note on Thursday, September 25th. Finally, Oppenheimer cut shares of Rhythm Pharmaceuticals from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating in a research report on Wednesday, November 5th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $125.60.</p>
<div class="lb-trans"><p>一些研究公司最近對 RYTM 發表了評論。Guggenheim 將 Rhythm Pharmaceuticals 的目標價格從 120.00 美元上調至 140.00 美元，並在週三的研究報告中給予該公司 “買入” 評級。Cowen 在 12 月 11 日星期四的研究報告中重申了對 Rhythm Pharmaceuticals 股票的 “買入” 評級。瑞銀集團在週三的研究報告中重申了對 Rhythm Pharmaceuticals 股票的 “買入” 評級。JMP Securities 在 9 月 25 日星期四的研究報告中將 Rhythm Pharmaceuticals 股票的目標價格從 135.00 美元上調至 142.00 美元，並給予該股票 “市場表現優於大盤” 評級。最後，Oppenheimer 在 11 月 5 日星期三的研究報告中將 Rhythm Pharmaceuticals 股票的評級從 “表現優於大盤” 下調至 “市場表現”。一位研究分析師給予該股票 “強烈買入” 評級，十六位分析師給予 “買入” 評級，一位分析師給予 “持有” 評級，一位分析師給予 “賣出” 評級。根據 MarketBeat.com 的數據，該股票的共識評級為 “適度買入”，共識目標價格為 125.60 美元。</p>
</div><p><strong>Read Our Latest Report on RYTM</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 RYTM 的最新報告</strong></p>
</div><h2>Rhythm Pharmaceuticals Profile</h2>
<div class="lb-trans"><h2>Rhythm Pharmaceuticals 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company's research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.</p>
<div class="lb-trans"><p>Rhythm Pharmaceuticals, Inc. 是一家臨牀階段的生物技術公司，致力於開發針對罕見遺傳性肥胖和代謝功能障礙的靶向療法。該公司的研究重點是黑色素皮質素-4 受體（MC4R）通路，該通路在調節食慾、能量消耗和體重方面發揮着核心作用。利用專有的肽技術，Rhythm 旨在為具有特定基因變異的患者提供精準治療，這些變異會干擾正常的體重調節。</p>
</div><p>The company's lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.</p>
<div class="lb-trans"><p>該公司的主要研究產品 setmelanotide 是一種選擇性 MC4R 激動劑，旨在恢復在 POMC、LEPR 和 PCSK1 等基因缺陷患者中的信號傳導。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>相關文章</h2>
</div><ul>
<li>Five stocks we like better than Rhythm Pharmaceuticals</li>
<li>Dividend Payout Ratio Calculator</li>
<li>Nike Beats on Earnings But Struggles in China and Faces Tariffs</li>
<li>What is the Shanghai Stock Exchange Composite Index?</li>
<li>Is the AI Boom a Bubble? These 2 Dividend Stocks Say No</li>
<li>3 Warren Buffett Stocks to Buy Now</li>
<li>4 High-Potential ETFs for 2026: Small Caps, Space Stocks, and More</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Rhythm Pharmaceuticals</li>
<li>股息支付比率計算器</li>
<li>耐克盈利超預期，但在中國市場面臨挑戰並遭遇關税</li>
<li>上海證券交易所綜合指數是什麼？</li>
<li>人工智能熱潮是泡沫嗎？這兩隻股息股票表示不是</li>
<li>現在值得購買的三隻沃倫·巴菲特股票</li>
<li>2026 年四隻高潛力 ETF：小型股、太空股票等</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UllUTQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=RYTM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Rhythm Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Rhythm Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Rhythm Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Rhythm Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rhythm Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前... 而 Rhythm Pharmaceuticals 並不在名單上。</p>
</div><p>While Rhythm Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Rhythm Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Assenagon Asset Management S.A. 出售了 13,870 股 Rhythm Pharmaceuticals, Inc.（股票代碼：RYTM）的股票